Page 26 - Tim Walbert News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Horizon Therapeutics to acquire Viela Bio for $3bn Horizon Therapeutics will acquire Viela Bio, helping expand its pipeline for long term growth. Through the acquisition, Dublin-headquartered Horizon Therapeutics will grow its rare disease medicine portfolio, gaining Uplizna (inebilizumab-cdon), the first and only FDA-approved B-cell-depleting humanized monoclonal antibody for the treatment of eye disease neuromyelitis optica spectrum disorder (NMOSD)  Viela Bio – which was founded in 2018 and is based in Gaithersburg, Maryland – has four therapeutic candida...

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition Viela's portfolio of assets includes FDA-approved NMOSD therapy Uplizna Horizon Therapeutics has entered into a definitive agreement to acquire Viela Bio for $3bn, in an effort to strengthen its rare disease portfolio. Viela Bio spun out of AstraZeneca’s Medimmune biologics unit in 2018 with six molecules and $250m in funding from a number of investors. Currently, Viela has one US Food and Drug Administration (FDA) approved asset – Uplizna (inebilizumab-cdon), which is indicated for the treatment of the rare conditio...

By Reuters Staff 2 Min Read (Reuters) -Horizon Therapeutics Plc on Monday agreed to buy Viela Bio Inc for about $3.05 billion in a move to expand its rare-disease portfolio. Viela’s only approved drug, Uplizna, is used to treat a rare, severe, neuroinflammatory disease named neuromyelitis optica spectrum disorder that attacks the optic nerve spinal cord and brain stem. “This acquisition represents a significant step forward in advancing our strategy – to expand our pipeline in order to accelerate our growth over the long term,” Horizon Chief Executive Officer Tim Walbert said. Horizon...

UPDATE: Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billion Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected to close by the end of the first quarter. “Adding Viela’s research and clinical development capabilities along with its deep, mid-stage biologics pipeline to our seasoned R&D and commercial teams, advances our transformation to an innovation-driven biotech company where we will build on the success of TEPEZZA and KRYSTEXXA to bolster ...

Dive Brief: Horizon Therapeutics has agreed to acquire Viela Bio, a spinout of AstraZeneca, in a deal that values the Maryland-based biotech at roughly $3 billion. Horizon will pay $53 per share for Viela, which in June won U.S. approval for Uplizna, a treatment for the rare autoimmune disease neuromyelitis optica spectrum disorder, or NMOSD. The price represents a roughly 53% premium for Viela, whose drug competes for market share with medicines from Roche and Alexion Pharmaceuticals.   The deal represents a quick exit for Viela's investors, among them AstraZeneca. The British drugmaker es...